Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2025)
Monopar Therapeutics (MNPR) reported Non-Current Assets of $254921.0 for Q4 2025, up 138.99% sequentially from $106666.0 in Q3 2025.
Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 9 years of Non-Current Assets data on file, last reported at $254921.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets changed N/A year-over-year to $254921.0; the trailing twelve-month figure through Dec 2025 stood at $488859.0 (changed N/A YoY), and the FY2025 full-year result was $254921.0, changed N/A from the prior year.
- Non-Current Assets climbed to $254921.0 in Q4 2025, from $106666.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $254921.0 in Q4 2025 to a low of $9102.0 in Q1 2025.
- A 4-year average of $72803.1 and a median of $68858.0 in 2021 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets climbed 22.52% in 2022 and plunged 79.35% in 2023, its largest moves.
- Tracing MNPR's Non-Current Assets over 4 years: stood at $68858.0 in 2021, then retreated by 11.08% to $61228.0 in 2022, then sank by 79.35% to $12646.0 in 2023, then jumped by 1915.82% to $254921.0 in 2025.
- Business Quant data shows MNPR's Non-Current Assets at $254921.0 in Q4 2025, $106666.0 in Q3 2025, and $118170.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 285.82 Mn |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - | 254,921.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 254,921.00 |
| Sep 30, 2025 | 106,666.00 |
| Jun 30, 2025 | 118,170.00 |
| Mar 31, 2025 | 9,102.00 |
| Dec 31, 2023 | 12,646.00 |
| Sep 30, 2023 | 25,088.00 |
| Jun 30, 2023 | 37,330.00 |
| Mar 31, 2023 | 49,376.00 |
| Dec 31, 2022 | 61,228.00 |
| Sep 30, 2022 | 72,889.00 |
| Jun 30, 2022 | 84,363.00 |
| Mar 31, 2022 | 53,694.00 |
| Sep 30, 2021 | 68,858.00 |
| Jun 30, 2021 | 68,858.00 |
| Mar 31, 2021 | 68,858.00 |
| Dec 31, 2020 | 68,858.00 |
| Sep 30, 2020 | 68,858.00 |
| Jun 30, 2020 | 73,050.00 |
| Mar 31, 2020 | 122,381.00 |
| Dec 31, 2019 | 122,381.00 |